Ipsen: UBS still on hold
(CercleFinance.com) - UBS maintains its neutral rating on the Ipsen stock with an unchanged target of 108 euros.
The analyst believes that the NAPOLI-3 data is in line with his expectations.
"Detailed NAPOLI-3 data presented at ASCO GI were in-line with our expectations. We continue to expect 1st-line use and our Onyvide forecast remains above cons.," UBS said.
Ipsen presented the NAPOLI 3 phase III trial of the Onivyde regimen, which showed positive survival results in previously untreated metastatic pancreatic ductal adenocarcinoma.
In short, these results represent a potential breakthrough in an aggressive and difficult-to-treat cancer.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.